Back to top
more

DermTech (DMTK)

(Delayed Data from NSDQ)

$0.61 USD

0.61
71,712

0.00 (-0.32%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $0.62 +0.01 (0.98%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -3.70% and 3.11%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

DocGo Inc. (DCGO) Q4 Earnings Lag Estimates

by Zacks Equity Research

DocGo Inc. (DCGO) delivered earnings and revenue surprises of -53.85% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.

DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.21% and 12.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Medpace (MEDP) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Medpace (MEDP) delivered earnings and revenue surprises of 1.58% and 6.99%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Pediatrix (MD) Down 4.2% Despite Q1 Earnings & Revenue Beat

by Zacks Equity Research

Investors are likely concerned about Pediatrix's (MD) lower enrollment in commercial insurance programs, escalating practice salaries and benefits and net borrowings.

DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -13.33% and 4.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.12% and 19.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.03% and 26.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 2.94% and 14.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline

by Zacks Equity Research

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agiliti (AGTI) Stock Jumps 5.5%: Will It Continue to Soar?

by Zacks Equity Research

Agiliti (AGTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.62% and -10.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate DermTech, Inc. (DMTK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 11.11% and 11.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will DermTech, Inc. (DMTK) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DermTech, Inc. (DMTK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.26% and 26.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DermTech, Inc. (DMTK) Moves 11.1% Higher: Will This Strength Last?

by Zacks Equity Research

DermTech, Inc. (DMTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 11.11% and 24.77%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

DermTech (DMTK) in Focus: Stock Moves 6% Higher

by Zacks Equity Research

DermTech (DMTK) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.